Breaking News

Sangamo BioSciences, CIRM In Strategic Pact

May 24, 2013

To develop ZFP therapeutic for blood disease

Sangamo BioSciences has received a $6.4 million Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to use its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic stem cells (HSCs) to develop a potential ZFP Therapeutic for beta-thalassemia.
 
The four-year grant provides matching funds for preclinical work to support an IND application and a Phase I trial in transfusion-dependent beta-thalassemia, a genetic blood disease caused by mutations in the beta-globin gene.
 
"CIRM support for this program is yet another major validation of our ZFP Therapeutics platform," said Edward Lanphier, Sangamo's president and chief executive officer. "The award will assist the development of our stem cell-based ZFP Therapeutic for the potential cure of thalassemia. Importantly, this same approach can be directly applied to related hemoglobinopathies such as sickle cell disease. We look forward to working with a team of world-renowned experts in this field, including the team at Children's Hospital & Research Center Oakland and our colleagues at CIRM, to bring this treatment through IND application and into a Phase I trial."

Related Contract Manufacturing:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research